Association between plasma alkaline phosphatase and C-reactive protein in Hong Kong Chinese

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 4, 2008, Pages 523-527

  Cheung, Bernard M Y ^a,e   Ong, Kwok Leung ^a   Cheung, Roberta V ^a   Wong, Louisa Y F ^a   Wat, Nelson M S ^a   Tam, Sidney ^b   Leung, Gabriel M ^a   Cheng, Chun Ho ^a   Woo, Jean ^c   Janus, Edward D ^d   Lau, Chu Pak ^a   Hing Lam, Tai ^a   Lam, Karen S L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Alkaline phosphatase; C reactive protein; Inflammation; Liver

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; ENZYME BLOOD LEVEL; FEMALE; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; SEX DIFFERENCE;

AGED; ALKALINE PHOSPHATASE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HONG KONG; HUMANS; INFLAMMATION; LIVER; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REFERENCE VALUES; RISK FACTORS; SEX FACTORS;

EID: 44949173227     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.111     Document Type: Article

References (36)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
2. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc 1998;279:1477-82.
3. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003;23:1255-61.
4. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144:537-47.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
7. Yudkin J, Stehouwer C, Emeis J, Coppack S. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
8. Han T, Sattar N, Williams K, Gonzalez-Villalpando C, Lean M, Haffner S. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016-21.
9. Corathers SD. Focus on diagnosis: the alkaline phosphatase level: nuances of a familiar test. Pediatr Rev 2006;27:382-4.
10. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Diabetes 2005;54:3140-7.
11. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25:193-7.
12. Janus ED, Watt NM, Lam KS, Cockram CS, Siu ST, Liu LJ, et al. The prevalence of diabetes, association with cardiovascular risk factors and implications of diagnostic criteria (ADA 1997 and WHO 1998) in a 1996 community-based population study in Hong Kong Chinese. Hong Kong Cardiovascular Risk Factor Steering Committee. American Diabetes Association. Diabet Med 2000;17:741-5.
13. Lam TH, Liu LJ, Janus ED, Bourke C, Hedley AJ. The relationship between fibrinogen and other coronary heart disease risk factors in a Chinese population. Atherosclerosis 1999;143:405-13.
14. Thomas GN, Schooling CM, McGhee SM, Ho SY, Cheung BM, Wat NM, et al. Identification of factors differentially associated with isolated impaired fasting glucose and isolated post-load impaired glucose tolerance: the Hong Kong Cardiovascular Risk Factor Study. Eur J Endocrinol 2006;155:1-11.
15. Thomas GN, Schooling CM, McGhee SM, Ho SY, Cheung BM, Wat NM, et al. Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study. Clin Endocrinol (Oxf) 2007;66:666-71.
16. Cheung BM, Wat NM, Man YB, Tam S, Thomas GN, Leung GM, et al. Development of diabetes in Chinese with the metabolic syndrome - a six year prospective study. Diabetes Care 2007;30:1430-6.
17. Cheung BM, Wat NM, Man YB, Tam S, Cheng CH, Leung GM, et al. Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2). Am J Hypertens 2008;21:17-22.
18. Wong LY, Leung RY, Ong KL, Cheung BM. Plasma levels of fibrinogen and C-reactive protein are related to interleukin-6 gene -572C>G polymorphism in subjects with and without hypertension. J Hum Hypertens 2007;21:875-82.
19. Wagenknecht LE, Mayer EJ, Rewers M, Haffner S, Selby J, Borok GM, et al. The Insulin Resistance Atherosclerosis Study: design, objectives and recruitment results. Ann Epidemiol 1995;5:464-72.
20. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191:235-40.
21. Domar U, Karpe F, Hamsten A, Stigbrand T, Olivecrona T. Human intestinal alkaline phosphatase - release to the blood is linked to lipid absorption, but removal from the blood is not linked to lipoprotein clearance. Eur J Clin Invest 1993;23:753-60.
22. Kaplow LS. Leukocyte alkaline phosphatase cytochemistry: applications and methods. Ann NY Acad Sci 1968;155:911-47.
23. Maldonado O, Demasi R, Maldonado Y, Taylor M, Troncale F, Vender R. Extremely high levels of alkaline phosphatase in hospitalized patients. J Clin Gastroenterol 1998;27:342-5.
24. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
25. Tang FT, Chen SR, Wu XQ, Wang TQ, Chen JW, Li J, et al. Hypercholesterolemia accelerates vascular calcification induced by excessive vitamin D via oxidative stress. Calcif Tissue Int 2006;79:326-39.
26. Kim SG, Kim HY, Seo JA, Lee KW, Oh JH, Kim NH, et al. Relationship between serum adiponectin concentration, pulse wave velocity and nonalcoholic fatty liver disease. Eur J Endocrinol 2005;152:225-31.
27. Ali AT, Paiker JE, Crowther NJ. The relationship between anthropometry and serum concentrations of alkaline phosphatase isoenzymes, liver-enzymes, albumin, and bilirubin. Am J Clin Pathol 2006;126:437-42.
28. Ali AT, Penny CB, Paiker JE, van Niekerk C, Smit A, Ferris WF, et al. Alkaline phosphatase is involved in the control of adipogenesis in the murine preadipocyte cell line, 3T3-L1. Clin Chim Acta 2005;354:101-9.
29. Ali AT, Penny CB, Paiker JE, Psaras G, Ikram F, Crowther NJ. The effect of alkaline phosphatase inhibitors on intracellular lipid accumulation in preadipocytes isolated from human mammary tissue. Ann Clin Biochem 2006;43:207-13.
30. Lopez-Bermejo A, Botas P, Funahashi T, Delgado E, Kihara S, Ricart W, et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf) 2004;60:256-63.
31. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care 2003;26:2015-20.
32. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007;49:1455-61.
33. Gordon T. Factors associated with serum alkaline phosphatase level. Arch Pathol Lab Med 1993;117:187-90.
34. Gullihorn L, Karpman R, Lippiello L. Differential effects of nicotine and smoke condensate on bone cell metabolic activity. J Orthop Trauma 2005;19:17-22.
35. Crilly RG, Jones MM, Horsman A, Nordin BE. Rise in plasma alkaline phosphatase at the menopause. Clin Sci (Lond) 1980;58:341-2.
36. Schiele F, Henny J, Hitz J, Petitclerc C, Gueguen R, Siest G. Total bone and liver alkaline phosphatases in plasma: biological variations and reference limits. Clin Chem 1983;29:634-41.